Skip to content

Intravitreal injection of rAAV2-ND1 for Leber hereditary optic neuropathy

Single intravitreal injection of rAAV2-ND1 for Leber hereditary optic neuropathy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041574
Enrollment
Unknown
Registered
2020-12-29
Start date
2021-01-08
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leber Optic Hereditary Neuropathy

Interventions

Group 1:Intravitreal injection of RAAV2-ND1 (1 × 109 Vg)
Group 2:Intravitreal injection of rAAV2-ND1 (1 × 1010 vg) 0.05ml

Sponsors

Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Met Leber's diagnostic criteria for hereditary optic neuropathy and was identified by gene sequencing as 3460 and other confirmed ND1 site mutations (3635 G A, 3733 G > A, 4136 A > G, 3571 C > T, 4171 C > A, 3697 G > A), without other treatment in the past 3 months and with no improvement in vision; 2. The fractional vision in both eyes was less than 0.3. 3. Aged >= 12 and <= 35 years, male or female, able to tolerate local anesthesia operation; 4. Consent not to use other drugs or treatments for the disease during the treatment period; 5. The patient and his legal representative participate voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with the following diseases: 1) Chronic diseases such as diabetes; 2) Severe primary diseases such as cardiovascular, cerebrovascular, liver and kidney; 3) Other systemic neurological diseases; 4) Patients in convalescence after heart surgery, etc.; 5) Patients with mental disorders; 6) Patients with other eye diseases; 7) Patients with Leber Plus; 2. Patients who have participated in other clinical studies in recent 3 months; 3. Alcoholism, smoking, drug use or a history of drug abuse or exposure to toxic substances; 4. Pregnant women, lactating women or those who plan to become pregnant within 12 months, and male patients who plan to have a child within 2 years; 5. Other reasons why the researcher considers it inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;visual field;

Countries

China

Contacts

Public ContactBin Li

Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China

scotoma16@163.com+86 13638673626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026